Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study

Background. The concurrent use of a postprandial insulin sensitizing agent, such as bromocriptine-QR, a quick release formulation of bromocriptine, a dopamine D2 receptor agonist, may offer a strategy to improve glycemic control and limit/reduce insulin requirement in type 2 diabetes (T2DM) patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Roe, Erin D., Chamarthi, Bindu, Raskin, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427808/
https://www.ncbi.nlm.nih.gov/pubmed/26060825
http://dx.doi.org/10.1155/2015/834903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427808/
https://www.ncbi.nlm.nih.gov/pubmed/26060825
http://dx.doi.org/10.1155/2015/834903

Ejemplares similares